Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction

Arcutis Biotherapeutics (NASDAQ: ARQT ) has been in the news recently following yet another FDA approval, further expanding the drug's existing label. The approved product ZORYVE is a PDE4 inhibitor, and physicians seem to favor this mechanism ofWe target small and microcap biopharmaceuticals companies where our advantage is greatest and mispricing is most intense. These young, often clinical stage companies have little to no institutional attention. Analyst coverage is often done by investment banks with v ...